Key facts
- Omnix Medical’s last known valuation is $22.8M (Nov 2020).
- It has raised $36.3M; the latest was Later Stage VC ($25.0M) in Oct 2025.
- Notable investors include European Innovation Council, OurCrowd, Innovation Authority, Entrée Capital, Consensus Business Group — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Omnix Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Omnix Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Omnix Medical
Developer of biopharmaceutical technology designed to combat drug-resistant bacterial infections. The company's platform develops next-generation antimicrobial peptides with enhanced stability, selectivity, and a novel mechanism of action that avoids resistance development, enabling healthcare providers to effectively treat resistant bacterial strains and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Jerusalem, Israel
- Founded
- 2015
- Employees
- 17
- Website
- omnixmedical.com/
- Ownership
- Privately Held (backing)
Omnix Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omnix Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omnix Medical in its N-PORT filings yet. We sweep new filings monthly.